Business
MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting
Allogeneic iNKTs, agenT-797, administered alone or in combination with anti-PD-1 therapy, shows activity in patients with refractory solid tumor cancers.In a
About this update from Mink Therapeutics, Inc.
[{"type":"text","content":"Allogeneic iNKTs, agenT-797, administered alone or in combination with anti-PD-1 therapy, shows activity in patients with refractory solid tumor cancers.In a patient with metastatic gastric cancer who had no response to treatment with pembrolizumab and nivolumab/FOLFOX, agenT-797 induced a partial response with 42% tumor shrinkage, which continues beyond 9 months.AgenT-797 was administered without toxic lymphodepletion, persists for ~8 weeks, and appears to generate and drive immune cells into the tumor for destruction of cancer cells.HC Wainwright to host KOL webcast with MiNK Therapeutics on Thursday, April 20th at 10:00am ET with Investigators Dr. Benedito Carneiro and Dr. Yelena Janjigian. NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, presented data at the American Association of Cancer Research (AACR) annual meeting, demonstrating the clinical benefit of allo-iNKTs, agenT-797, alone and in combination with anti-PD-1 in patients with refractory non-small cell lung cancer (NSCLC), testicular, and gastric cancers. “MiNK's groundbreaking research presented at AACR showcases a new era in cancer treatment with the potential to transform the lives of patients who have failed traditional therapies, including anti-PD-1 treatment,\" said Dr. Jennifer Buell, President and CEO at MiNK. \"Our pioneering off-the-shelf iNKT cell therapy, agenT-797, has demonstrated clinical benefit in solid tumor cancers, and we are committed to expediting its development. With a scalable manufacturing process and a favorable safety profile, we look forward to collaborating with world-leading experts to expand our trials and bring new hope to patients with anti-PD-1 refractory NSCLC, testicular, and gastric cancers.\" In a phase 1/2 trial, patients received a single infusion of agenT-797, alone or in combination with pembro or nivo, without lymphodepletion. Patients were heavily pretreated with a median of 4 prior lines of therapy and were unresponsive to prior anti-PD-1 therapy. The results showed that agenT-797 promoted durable responses, including a partial response and tumor reductio...